Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin to Enhance Engraftment After Umbilical Cord Blood Transplantation
NCT00862719Phase 2Completed
- Sponsor
- Indiana University School of Medicine
- Start
- Mar 2009
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sitagliptin in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and 4 more (3 arms), sponsored by Indiana University School of Medicine. Primary endpoint: Cumulative Incidence of Patients With Engraftment by Day +30 Following Transplant at 30 days. Started Mar 2009; status: completed.
02
Drugs
sitagliptin
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)chronic myeloid leukemia (CML)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00862719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00862719.